Document text
Principal Investigator: MICHAEL C SNELLER
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2023
Award: $648,551
Funding agency: National Institute of Allergy and Infectious Diseases
COVID-19 was identified in early 2020, and this newly recognized viral disease went on to become a worldwide pandemic. The clinical characteristics and spectrum of disease severity of acute COVID-19 were being defined, with a significant portion of those infected developing severe disease manifestations including pneumonia, acute respiratory distress syndrome with respiratory failure, and, in some cases, death. Very little was known about possible clinical sequelae that could persist after resolution of the acute infection. In addition, the characteristics of the initial cellular immune and antibody response to SARS-CoV-2 (the virus that causes COVID-19) were being defined and it was not known if the immune responses generated by infection provides long-term protective immunity.
We mobilized quickly to study this new infection and designed a study to establish a longitudinal cohort of patients who recovered from COVID-19 to characterize the medical sequalae and persistent symptoms following recovery from COVID-19; estimate the incidence and risk factors for post-COVID-19 medical sequalae; and characterize antibody and cell-mediated immune responses to SARS-CoV-2 in disease survivors and these responses over time.
Participants in the study are self-referred adults with laboratory-documented SARS-CoV-2 infection who were at least 6 weeks from symptom onset were enrolled regardless of presence of symptoms or severity of the acute illness. The control group includes persons with no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, who are recruited regardless of their current health status. All participants have the same evaluations regardless of presence of symptoms, including physical examination, laboratory tests and questionnaires, cognitive function testing, and cardiopulmonary evaluation. Samples of peripheral blood mononuclear cells, serum, and plasma has been collected from all participants.
The baseline findings of the study were published in July 2022 at the Annals of Internal Medicine. These include the results from 309 participants who enrolled during the first year of the study. These are 189 patients with COVID-19 (12% of whom were hospitalized during acute illness) and 120 controls. At enrollment, symptoms consistent with postacute sequelae of SARS-CoV-2 infection (PASC) were reported by 55% of the COVID-19 cohort and 13% of control participants. Increased risk for PASC was noted in women and those with a history of anxiety disorder. Participants with findings meeting the definition of PASC reported lower quality of life on standardized testing. Abnormal findings on physical examination and diagnostic testing were uncommon. Neutralizing antibody levels to spike protein were negative in 27% of the unvaccinated COVID-19 cohort and none of the vaccinated COVID-19 cohort. Exploratory studies found no evidence of persistent viral infection, autoimmunity, or abnormal immune activation in participants with PASC. Limitations include the possibilities that persons with PASC may have been more motivated to enroll (leading to overestimation of PASC prevalence) and that PASC that resolved before enrollment was not captured in the study (leading to underestimation of PASC prevalence). The study showed that there is a high burden of persistent symptoms in persons after COVID-19, but extensive diagnostic evaluation revealed no specific cause of reported symptoms in most cases.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><ARDS><Acute><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult><Adult ARDS><Adult Human><Adult RDS><Adult Respiratory Distress Syndrome><Airway failure><Antibodies><Antibody Response><Anxiety Disorders><Autoimmune Status><Autoimmunity><Blood Plasma><Blood Serum><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><CV19><Cardiopulmonary><Cessation of life><Characteristics><Clinical><CoV-2><CoV2><Control Groups><Da Nang Lung><Death><Diagnostic><Diagnostic tests><Disease><Disorder><Enrollment><Evaluation><Evolution><Future><Health Status><History><Hospital Admission><Hospitalization><Household><Immune Cell Activation><Immune response><Immunity><Immunological response><Incidence><Infection><Internal Medicine><Laboratories><Level of Health><Long-term cohort><Long-term cohort study><Longitudinal Studies><Longitudinal cohort><Longitudinal cohort study><Longterm cohort><Longterm cohort study><Mediating><Medical><Medical Inspection><Mental Health><Mental Hygiene><PASC><PBMC><Participant><Patients><Peripheral Blood Mononuclear Cell><Persons><Physical Examination><Plasma><Plasma Serum><Pneumonia><Post Acute Sequelae of COVID19><Post Acute Sequelae of SARS-CoV-2><Post Acute Sequelae of SARS-CoV2><Post Acute Sequelae of severe acute respiratory syndrome coronavirus 2><Post-Acute Sequelae of SARS-CoV-2 Infection><Prevalence><Proteins><Psychological Health><Publishing><QOL><Quality of life><Questionnaires><Recording of previous events><Recovery><Reporting><Resolution><Respiratory Failure><Reticuloendothelial System, Serum, Plasma><Risk><Risk Factors><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serology><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Severities><Severity of illness><Shock Lung><Standardization><Stiff lung><Survivors><Symptoms><T-Cells><T-Lymphocyte><Testing><Time><Trauma><Vaccinated><Viral Diseases><Virus><Virus Diseases><Woman><Wuhan coronavirus><acute infection><adulthood><adverse sequelae of COVID><adverse sequelae of COVID-19><adverse sequelae of coronavirus disease><adverse sequelae of coronavirus disease 2019><cell mediated immune response><chronic COVID-19 sequelae><chronic symptom><cognitive function><cohort><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><design><designing><disease severity><enroll><hCoV19><histories><host response><immune activation><immune system response><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><long haul sequelae of COVID-19><long haul sequelae of coronavirus disease 2019><long-term sequelae of COVID-19><long-term sequelae of SARS-CoV-2><long-term sequelae of coronavirus disease 2019><long-term sequelae of severe acute respiratory syndrome coronavirus 2><long-term study><longitudinal outcome studies><longterm study><meeting><meetings><nCoV2><neutralizing antibody><non vaccinated><not vaccinated><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><persistent symptom><physical examinations><post-COVID><post-COVID-19><post-acute sequelae following SARS-CoV-2 infection><post-acute sequelae of COVID-19><post-acute sequelae of acute COVID infection><post-acute sequelae of coronavirus disease 2019><post-coronavirus disease 2019><recruit><resolutions><response><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><thymus derived lymphocyte><unvaccinated><viral infection><virus infection><virus-induced disease><wet lung>